Related Experiment Videos
Progressive polyradiculoneuropathy: treatment with Azathioprine
Australian and New Zealand Journal of Medicine
|April 1, 1979
Summary
A rare, progressive form of chronic inflammatory polyradiculoneuropathy (CIP) showed dramatic improvement with Azathioprine after steroids failed. This suggests aggressive immunosuppressive therapy may improve outcomes in severe CIP cases.
Area of Science:
- Neurology
- Immunology
Background:
- Chronic inflammatory polyradiculoneuropathy (CIP) is a rare neurological disorder.
- Progressive forms of CIP are uncommon and often have poor prognoses despite standard treatments like steroids.
Observation:
- A 64-year-old male presented with rapidly progressing quadriplegia due to CIP over seven months, unresponsive to steroid therapy.
- Initiation of Azathioprine treatment led to significant clinical improvement within six weeks.
Findings:
- The patient's dramatic recovery suggests Azathioprine is effective in managing relentlessly progressive CIP.
- Immunologically, progressive CIP shares similarities with relapsing CIP and acute inflammatory polyradiculoneuropathy (AIP).
Implications:
- Cytotoxic immunosuppressive agents like Azathioprine may offer a definitive treatment option for CIP cases progressing beyond 4-5 weeks.
- Aggressive immunosuppressive therapy, potentially including Azathioprine, could significantly improve the historically poor prognosis of severe, progressive CIP, which has high mortality and low recovery rates with conventional treatments.